Characterization of preclinical models of prostate cancer using PET-based molecular imaging.
about
Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
P2860
Characterization of preclinical models of prostate cancer using PET-based molecular imaging.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Characterization of preclinica ...... g PET-based molecular imaging.
@en
Characterization of preclinica ...... g PET-based molecular imaging.
@nl
type
label
Characterization of preclinica ...... g PET-based molecular imaging.
@en
Characterization of preclinica ...... g PET-based molecular imaging.
@nl
prefLabel
Characterization of preclinica ...... g PET-based molecular imaging.
@en
Characterization of preclinica ...... g PET-based molecular imaging.
@nl
P2093
P50
P1476
Characterization of preclinica ...... g PET-based molecular imaging.
@en
P2093
Ferruccio Fazio
Massimo Freschi
Michela Lecchi
Rodrigo Hess Michelini
Rosa M Moresco
Sara Belloli
P2888
P304
P356
10.1007/S00259-009-1091-3
P577
2009-03-11T00:00:00Z